PPAR- γ agonists and their effects on igf-i receptor signaling: Implications for cancer

PPAR Research

Volumn , Issue , 2009, Pages

  Belfiore, A ^a   Genua, M ^b   Malaguarnera, R ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CIGLITAZONE; CLOFIBRIC ACID; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; NANENOPIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TROGLITAZONE; UNCLASSIFIED DRUG; WARFARIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOAVAILABILITY; CANCER CELL; CANCER GROWTH; CANCER RISK; CELL PROLIFERATION; CLINICAL TRIAL; DOWN REGULATION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER TOXICITY; MALIGNANT NEOPLASTIC DISEASE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; TUMOR DIFFERENTIATION;

EID: 68949128792     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2009/830501     Document Type: Review

References (212)

1. Maloney E. K., McLaughlin J. L., Dagdigian N. E., An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation Cancer Research 2003 63 16 5073 5083
2. Garber K., IGF-1: old growth factor shines as new drug target Journal of the National Cancer Institute 2005 97 11 790 792
3. Soos M. A., Nave B. T., Siddle K., Immunological studies of type I IGF receptors and insulin receptors: characterisation of hybrid and atypical receptor subtypes Advances in Experimental Medicine and Biology 1993 343 145 157
4. Pisani P., Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies Archives of Physiology and Biochemistry 2008 114 1 63 70
5. Huang Z., Bodkin N. L., Ortmeyer H. K., Hansen B. C., Shuldiner A. R., Hyperinsulinemia is associated with altered insulin receptor mRNA splicing in muscle of the spontaneously obese diabetic rhesus monkey The Journal of Biological Chemistry 1994 94 3 1289 1296
6. Fair A. M., Dai Q., Shu X.-O., Energy balance, insulin resistance biomarkers, and breast cancer risk Cancer Detection and Prevention 2007 31 3 214 219
7. Vigneri P., Frasca F., Sciacca L., Frittitta L., Vigneri R., Obesity and cancer Nutrition, Metabolism and Cardiovascular Diseases 2006 16 1 1 7
8. Strickler H. D., Wylie-Rosett J., Rohan T., The relation of type 2 diabetes and cancer Diabetes Technology and Therapeutics 2001 3 2 263 274
9. Yki-Jrvinen H., Thiazolidinediones The New England Journal of Medicine 2004 351 11 1106 1118
10. Burstein H. J., Demetri G. D., Mueller E., Sarraf P., Spiegelman B. M., Winer E. P., Use of the peroxisome proliferator-activated receptor (PPAR) ligand troglitazone as treatment for refractory breast cancer: a phase II study Breast Cancer Research and Treatment 2003 79 3 391 397
11. Butler R., Mitchell S. H., Tindall D. J., Young C. Y. F., Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor ligand, 15-deoxy- 12,14 -prostaglandin J2 Cell Growth and Differentiation 2000 11 1 49 61
12. Chang T.-H., Szabo E., Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor in non-small cell lung cancer Cancer Research 2000 60 4 1129 1138
13. Heaney A. P., Fernando M., Yong W. H., Melmed S., Functional PPAR- receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas Nature Medicine 2002 8 11 1281 1287
14. Inoue K.-I., Kawahito Y., Tsubouchi Y., Expression of peroxisome proliferator-activated receptor in renal cell carcinoma and growth inhibition by its agonists Biochemical and Biophysical Research Communications 2001 287 3 727 732
15. Kawa S., Nikaido T., Unno H., Usuda N., Nakayama K., Kiyosawa K., Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR ligand troglitazone Pancreas 2002 24 1 1 7
16. Li M.-Y., Deng H., Zhao J.-M., Dai D., Tan X.-Y., Peroxisome proliferator-activated receptor gamma ligands inhibit cell growth and induce apoptosis in human liver cancer BEL-7402 cell World Journal of Gastroenterology 2003 9 8 1683 1688
17. Mueller E., Smith M., Sarraf P., Effects of ligand activation of peroxisome proliferator-activated receptor in human prostate cancer Proceedings of the National Academy of Sciences of the United States of America 2000 97 20 10990 10995
18. Shimada T., Kojima K., Yoshiura K., Hiraishi H., Terano A., Characteristics of the peroxisome proliferator activated receptor (PPAR ) ligand induced apoptosis in colon cancer cells Gut 2002 50 5 658 664
19. Valentinis B., Baserga R., IGF-I receptor signalling in transformation and differentiation Molecular Pathology 2001 54 3 133 137
20. Sara V. R., Hall K., Insulin-like growth factors and their binding proteins Physiological Reviews 1990 70 3 591 614
21. Ullrich A., Bell J. R., Chen E. Y., Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes Nature 1985 313 6005 756 761
22. Ullrich A., Gray A., Tam A. W., Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity The EMBO Journal 1986 5 10 2503 2512
23. Kato H., Faria T. N., Stannard B., Roberts C. T. Jr., LeRoith D., Essential role of tyrosine residues 1131, 1135, and 1136 of the insulin-like growth factor-I (IGF-I) receptor in IGF-I action Molecular Endocrinology 1994 8 1 40 50
24. Moller D. E., Yokota A., Caro J. F., Flier J. S., Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man Molecular Endocrinology 1989 3 8 1263 1269
25. Mosthaf L., Grako K., Dull T. J., Coussens L., Ullrich A., McClain D. A., Functionally distinct insulin receptors generated by tissue-specific alternative splicing The EMBO Journal 1990 9 8 2409 2413
26. Sbraccia P., Giaccari A., DAdamo M., Expression of the two insulin receptor isoforms is not altered in the skeletal muscle and liver of diabetic rats Metabolism 1998 47 2 129 132
27. Pandini G., Frasca F., Mineo R., Sciacca L., Vigneri R., Belfiore A., Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved The Journal of Biological Chemistry 2002 277 42 39684 39695
28. Sciacca L., Prisco M., Wu A., Belfiore A., Vigneri R., Baserga R., Signaling differences from the A and B isoforms of the insulin receptor (IR) in 32D cells in the presence or absence of IR substrate-1 Endocrinology 2003 144 6 2650 2658
29. Denley A., Bonython E. R., Booker G. W., Structural determinants for high-affinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR Molecular Endocrinology 2004 18 10 2502 2512
30. Drakas R., Tu X., Baserga R., Control of cell size through phosphorylation of upstream binding factor 1 by nuclear phosphatidylinositol 3-kinase Proceedings of the National Academy of Sciences of the United States of America 2004 101 25 9272 9276
31. Kahn C. R., The Gordon Wilson Lecture. Lessons about the control of glucose homeostasis and the pathogenesis of diabetes from knockout mice Transactions of the American Clinical and Climatological Association 2003 114 125 148
32. Sussenbach J. S., Rodenburg R. J. T., Scheper W., Holthuizen P., Transcriptional and post-transcriptional regulation of the human IGF-II gene expression Advances in Experimental Medicine and Biology 1993 343 63 71 (Pubitemid 24059277)
33. Zhang L., Kashanchi F., Zhan Q., Regulation of insulin-like growth factor II P3 promoter by p53: a potential mechanism for tumorigenesis Cancer Research 1996 56 6 1367 1373
34. Probst-Hensch N. M., Yuan J.-M., Stanczyk F. Z., Gao Y.-T., Ross R. K., Yu M. C., IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai British Journal of Cancer 2001 85 11 1695 1699
35. Conover C. A., Powell D. R., Insulin-like growth factor (IGF)-binding protein-3 blocks IGF-I-induced receptor down-regulation and cell densitization in cultured bovine fibroblasts Endocrinology 1991 129 2 710 716
36. Schairer C., Hill D., Sturgeon S. R., Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women International Journal of Cancer 2004 108 5 773 779
37. LeRoith D., Roberts C. T. Jr., The insulin-like growth factor system and cancer Cancer Letters 2003 195 2 127 137
38. Ottensmeyer F. P., Beniac D. R., Luo R. Z.-T., Yip C. C., Mechanism of transmembrane signaling: insulin binding and the insulin receptor Biochemistry 2000 39 40 12103 12112
39. Liu F., Roth R. A., Binding of SH2 containing proteins to the insulin receptor: a new way for modulating insulin signalling Molecular and Cellular Biochemistry 1998 182 1-2 73 78
40. Kanzaki M., Pessin J. E., Signal integration and the specificity of insulin action Cell Biochemistry and Biophysics 2001 35 2 191 209
41. Harrington L. S., Findlay G. M., Lamb R. F., Restraining PI3K: mTOR signalling goes back to the membrane Trends in Biochemical Sciences 2005 30 1 35 42
42. Ceresa B. P., Pessin J. E., Insulin regulation of the Ras activation/inactivation cycle Molecular and Cellular Biochemistry 1998 182 1-2 23 29
43. Hay N., Sonenberg N., Upstream and downstream of mTOR Genes and Development 2004 18 16 1926 1945
44. Sarbassov D. D., Ali S. M., Sabatini D. M., Growing roles for the mTOR pathway Current Opinion in Cell Biology 2005 17 6 596 603
45. Wang X., Proud C. G., The mTOR pathway in the control of protein synthesis Physiology 2006 21 5 362 369
46. Barthel A., Schmoll D., Unterman T. G., FoxO proteins in insulin action and metabolism Trends in Endocrinology and Metabolism 2005 16 4 183 189
47. Myatt S. S., Lam E. W.-F., The emerging roles of forkhead box (Fox) proteins in cancer Nature Reviews Cancer 2007 7 11 847 859
48. Nakae J., Park B.-C., Accili D., Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a wortmannin-sensitive pathway The Journal of Biological Chemistry 1999 274 23 15982 15985
49. Zou Y., Tsai W. B., Cheng C. J., Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis Breast Cancer Research 2008 10 1, article R21
50. Burgering B. M. T., Kops G. J. P. L., Cell cycle and death control: long live forkheads Trends in Biochemical Sciences 2002 27 7 352 360
51. Kino T., De Martino M. U., Charmandari E., Ichijo T., Outas T., Chrousos G. P., HIV-1 accessory protein Vpr inhibits the effect of insulin on the Foxo subfamily of forkhead transcription factors by interfering with their binding to 14-3-3 proteins: potential clinical implications regarding the insulin resistance of HIV-1-infected patients Diabetes 2005 54 1 23 31
52. Kops G. J. P. L., de Ruiter N. D., De Vries-Smits A. M. M., Powell D. R., Bos J. L., Burgering B. M. Th., Direct control of the forkhead transcription faotor AFX by protein kinase B Nature 1999 398 6728 630 634
53. Stambolic V., Suzuki A., de la Pompa J. L., Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN Cell 1998 95 1 29 39
54. Simpson L., Parsons R., PTEN: life as a tumor suppressor Experimental Cell Research 2001 264 1 29 41
55. Kaburagi Y., Yamamoto-Honda R., Tobe K., The role of the NPXY motif in the insulin receptor in tyrosine phosphorylation of insulin receptor substrate-1 and Shc Endocrinology 1995 136 8 3437 3443
56. Kondoh K., Torii S., Nishida E., Control of MAP kinase signaling to the nucleus Chromosoma 2005 114 2 86 91
57. Brunet A., Roux D., Lenormand P., Dowd S., Keyse S., Pouyssgur J., Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry The EMBO Journal 1999 18 3 664 674
58. Roux P. P., Blenis J., ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions Microbiology and Molecular Biology Reviews 2004 68 2 320 344
59. Chan J. M., Stampfer M. J., Giovannucci E., Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study Science 1998 279 5350 563 566
60. Hankinson S. E., Willett W. C., Colditz G. A., Circulating concentrations of insulin-like growth factor-I and risk of breast cancer The Lancet 1998 351 9113 1393 1396
61. Ma J., Pollak M. N., Giovannucci E., Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3 Journal of the National Cancer Institute 1999 91 7 620 625
62. Yu H., Spitz M. R., Mistry J., Gu J., Hong W. K., Wu X., Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis Journal of the National Cancer Institute 1999 91 2 151 156
63. Zhao H., Grossman H. B., Spitz M. R., Lerner S. P., Zhang K., Wu X., Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk The Journal of Urology 2003 169 2 714 717
64. Loeper S., Ezzat S., Acromegaly: re-thinking the cancer risk Reviews in Endocrine and Metabolic Disorders 2008 9 1 41 58
65. Bruce W. R., Wolever T. M. S., Giacca A., Mechanisms linking diet and colorectal cancer: the possible role of insulin resistance Nutrition and Cancer 2000 37 1 19 26
66. Goodwin P. J., Ennis M., Pritchard K. I., Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study Journal of Clinical Oncology 2002 20 1 42 51
67. Jones R. A., Campbell C. I., Gunther E. J., Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation Oncogene 2007 26 11 1636 1644
68. Ouban A., Muraca P., Yeatman T., Coppola D., Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas Human Pathology 2003 34 8 803 808
69. Papa V., Pezzino V., Costantino A., Elevated insulin receptor content in human breast cancer The Journal of Biological Chemistry 1990 86 5 1503 1510
70. Sciacca L., Costantino A., Pandini G., Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism Oncogene 1999 18 15 2471 2479
71. Frasca F., Pandini G., Scalia P., Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells Molecular and Cellular Biology 1999 19 5 3278 3288
72. Pandini G., Vigneri R., Costantino A., Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling Clinical Cancer Research 1999 5 7 1935 1944
73. Arteaga C. L., Osborne C. K., Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor Cancer Research 1989 49 22 6237 6241
74. Cullen K. J., Allison A., Martire I., Ellis M., Singer C., Insulin-like growth factor expression in breast cancer epithelium and stroma Breast Cancer Research and Treatment 1992 22 1 21 29
75. Bates P., Fisher R., Ward A., Richardson L., Hill D. J., Graham C. F., Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II) British Journal of Cancer 1995 72 5 1189 1193
76. Hadsell D. L., Murphy K. L., Bonnette S. G., Reece N., Laucirica R., Rosen J. M., Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis Oncogene 2000 19 7 889 898
77. Moorehead R. A., Fata J. E., Johnson M. B., Khokha R., Inhibition of mammary epithelial apoptosis and sustained phosphorylation of Akt/PKB in MMTV-IGF-II transgenic mice Cell Death and Differentiation 2001 8 1 16 29
78. Neuenschwander S., Schwartz A., Wood T. L., Roberts C. T. Jr., Henninghausen L., LeRoith D., Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model The Journal of Biological Chemistry 1996 97 10 2225 2232
79. OConnor R., Fennelly C., Krause D., Regulation of survival signals from the insulin-like growth factor-I receptor Biochemical Society Transactions 2000 28 2 47 51
80. Coats S., Flanagan W. M., Nourse J., Roberts J. M., Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle Science 1996 272 5263 877 880
81. Dupont J., Dunn S. E., Barrett J. C., LeRoith D., Microarray analysis and identification of novel molecules involved in insulin-like growth factor-1 receptor signaling and gene expression Recent Progress in Hormone Research 2003 58 325 342
82. Stawowy P., Kallisch H., Kilimnik A., Proprotein convertases regulate insulin-like growth factor 1-induced membrane-type 1 matrix metalloproteinase in VSMCs via endoproteolytic activation of the insulin-like growth factor-1 receptor Biochemical and Biophysical Research Communications 2004 321 3 531 538
83. Zhang X., Lin M., Van Golen K. L., Yoshioka K., Itoh K., Yee D., Multiple signaling pathways are activated during insulin-like growth factor-I (IGF-I) stimulated breast cancer cell migration Breast Cancer Research and Treatment 2005 93 2 159 168
84. Baserga R., Peruzzi F., Reiss K., The IGF-1 receptor in cancer biology International Journal of Cancer 2003 107 6 873 877
85. Kaleko M., Rutter W. J., Miller A. D., Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation Molecular and Cellular Biology 1990 10 2 464 473
86. Liu J.-L., Blakesley V. A., Gutkind J. S., LeRoith D., The constitutively active mutant G13 transforms mouse fibroblast cells deficient in insulin-like growth factor-I receptor The Journal of Biological Chemistry 1997 272 47 29438 29441
87. Sell C., Dumenil G., Deveaud C., Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts Molecular and Cellular Biology 1994 14 6 3604 3612
88. Giorgino F., Belfiore A., Milazzo G., Overexpression of insulin receptors in fibroblast and ovary cells induces a ligand-mediated transformed phenotype Molecular Endocrinology 1991 5 3 452 459
89. Mastick C. C., Kato H., Roberts C. T. Jr., LeRoith D., Saltiel A. R., Insulin and insulin-like growth factor-I receptors similarly stimulate deoxyribonucleic acid synthesis despite differences in cellular protein tyrosine phosphorylation Endocrinology 1994 135 1 214 222
90. Milazzo G., Giorgino F., Damante G., Insulin receptor expression and function in human breast cancer cell lines Cancer Research 1992 52 14 3924 3930
91. Pillemer G., Lugasi-Evgi H., Scharovsky G., Naor D., Insulin dependence of murine lymphoid T-cell leukemia International Journal of Cancer 1992 50 1 80 85
92. Benoliel A.-M., Kahn-Perles B., Imbert J., Verrando P., Insulin stimulates haptotactic migration of human epidermal keratinocytes through activation of NF- B transcription factor Journal of Cell Science 1997 110, part 17 2089 2097
93. Sciacca L., Mineo R., Pandini G., Murabito A., Vigneri R., Belfiore A., In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A Oncogene 2002 21 54 8240 8250
94. Casa A. J., Dearth R. K., Litzenburger B. C., Lee A. V., Cui X., The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance Frontiers in Bioscience 2008 13 9 3273 3287
95. Yu D., Watanabe H., Shibuya H., Miura M., Redundancy of radioresistant signaling pathways originating from insulin-like growth factor I receptor The Journal of Biological Chemistry 2003 278 9 6702 6709
96. Theocharis S., Margeli A., Vielh P., Kouraklis G., Peroxisome proliferator-activated receptor- ligands as cell-cycle modulators Cancer Treatment Reviews 2004 30 6 545 554
97. Michalik L., Desvergne B., Wahli W., Peroxisome-proliferator-activated receptors and cancers: complex stories Nature Reviews Cancer 2004 4 1 61 70
98. Zhou J., Wilson K. M., Medh J. D., Genetic analysis of four novel peroxisome proliferator activated receptor- splice variants in monkey macrophages Biochemical and Biophysical Research Communications 2002 293 1 274 283
99. Corton J. C., Anderson S. P., Stauber A., Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators Annual Review of Pharmacology and Toxicology 2000 40 491 518
100. Kodera Y., Takeyama K.-I., Murayama A., Suzawa M., Masuhiro Y., Kato S., Ligand type-specific interactions of peroxisome proliferator-activated receptor with transcriptional coactivators The Journal of Biological Chemistry 2000 275 43 33201 33204
101. Yang W., Rachez C., Freedman L. P., Discrete roles for peroxisome proliferator-activated receptor and retinoid X receptor in recruiting nuclear receptor coactivators Molecular and Cellular Biology 2000 20 21 8008 8017
102. Kliewer S. A., Forman B. M., Blumberg B., Differential expression and activation of a family of murine peroxisome proliferator-activated receptors Proceedings of the National Academy of Sciences of the United States of America 1994 91 15 7355 7359
103. Yokoyama Y., Xin B., Shigeto T., Clofibric acid, a peroxisome proliferator-activated receptor ligand, inhibits growth of human ovarian cancer Molecular Cancer Therapeutics 2007 6 4 1379 1386
104. Keller H., Dreyer C., Medin J., Mahfoudi A., Ozato K., Wahli W., Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers Proceedings of the National Academy of Sciences of the United States of America 1993 90 6 2160 2164
105. Keller H., Mahfoudi A., Dreyer C., Peroxisome proliferator-activated receptors and lipid metabolism Annals of the New York Academy of Sciences 1993 684 157 173
106. Hatton J. L., Yee L. D., Clinical use of PPAR ligands in cancer PPAR Research 2008 2008 13
107. Clay C. E., Namen A. M., Atsumi G.-I., Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells Carcinogenesis 1999 20 10 1905 1911
108. Li M., Lee T. W., Yim A. P. C., Mok T. S. K., Chen G. G., Apoptosis induced by troglitazone is both peroxisome proliterator-activated receptor- -and ERK-dependent in human non-small lung cancer cells Journal of Cellular Physiology 2006 209 2 428 438
109. Aiello A., Pandini G., Frasca F., Peroxisomal proliferator-activated receptor- agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells Endocrinology 2006 147 9 4463 4475
110. Weng J.-R., Chen C.-Y., Pinzone J. J., Ringel M. D., Chen C.-S., Beyond peroxisome proliferator-activated receptor signaling: the multi-facets of the antitumor effect of thiazolidinediones Endocrine-Related Cancer 2006 13 2 401 413
111. Chen F., Harrison L. E., Ciglitazone-induced cellular anti-proliferation increases p27 kip1 protein levels through both increased transcriptional activity and inhibition of proteasome degradation Cellular Signalling 2005 17 7 809 816
112. Musgrove E. A., Lee C. S. L., Buckley M. F., Sutherland R. L., Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle Proceedings of the National Academy of Sciences of the United States of America 1994 91 17 8022 8026
113. Kawakami S., Arai G., Hayashi T., PPAR ligands suppress proliferation of human urothelial basal cells in vitro Journal of Cellular Physiology 2002 191 3 310 319
114. Yang F.-G., Zhang Z.-W., Xin D.-Q., Peroxisome proliferator-activated receptor ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines Acta Pharmacologica Sinica 2005 26 6 753 761
115. Mueller E., Sarraf P., Tontonoz P., Terminal differentiation of human breast cancer through PPAR Molecular Cell 1998 1 3 465 470
116. Zhang W., Zhang H., Xing L., Influence of ciglitazone on A549 cells growth in vitro and in vivo and mechanism Journal of Huazhong University of Science and Technology. Medical Sciences 2006 26 1 36 39
117. Ohta T., Elnemr A., Yamamoto M., Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, modulates the E-cadherin/beta- catenin system in a human pancreatic cancer cell line, BxPC-3 International Journal of Oncology 2002 21 1 37 42
118. Piwien-Pilipuk G., Van Mater D., Ross S. E., MacDougald O. A., Schwartz J., Growth hormone regulates phosphorylation and function of CCAAT/enhancer-binding protein by modulating Akt and glycogen synthase kinase-3 The Journal of Biological Chemistry 2001 276 22 19664 19671
119. Moldes M., Zuo Y., Morrison R. F., Peroxisome-proliferator-activated receptor suppresses Wnt/ -catenin signalling during adipogenesis Biochemical Journal 2003 376 3 607 613
120. Liu J., Wang H., Zuo Y., Farmer S. R., Functional interaction between peroxisome proliferator-activated receptor and -catenin Molecular and Cellular Biology 2006 26 15 5827 5837
121. Lu D., Cottam H. B., Corr M., Carson D. A., Repression of -catenin function in malignant cells by nonsteroidal antiinflammatory drugs Proceedings of the National Academy of Sciences of the United States of America 2005 102 51 18567 18571
122. Ross S. E., Hemati N., Longo K. A., Inhibition of adipogenesis by Wnt signaling Science 2000 289 5481 950 953
123. Panigrahy D., Singer S., Shen L. Q., PPAR ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis The Journal of Clinical Investigation 2002 110 7 923 932
124. Xin X., Yang S., Kowalski J., Gerritsen M. E., Peroxisome proliferator-activated receptor ligands are potent inhibitors of angiogenesis in vitro and in vivo The Journal of Biological Chemistry 1999 274 13 9116 9121
125. Duan S. Z., Ivashchenko C. Y., Usher M. G., Mortensen R. M., PPAR-gamma in the cardiovascular system PPAR Research 2008 2008 10
126. Reginato M. J., Krakow S. L., Bailey S. T., Lazar M. A., Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor The Journal of Biological Chemistry 1998 273 4 1855 1858
127. Hsi L. C., Wilson L., Nixon J., Eling T. E., 15-lipoxygenase-1 metabolites down-regulate peroxisome proliferator-activated receptor via the MAPK signaling pathway The Journal of Biological Chemistry 2001 276 37 34545 34552
128. Aouadi M., Laurent K., Prot M., Le Marchand-Brustel Y., Bintruy B., Bost F., Inhibition of p38MAPK increases adipogenesis from embryonic to adult stages Diabetes 2006 55 2 281 289
129. Floyd Z. E., Stephens J. M., Interferon- -mediated activation and ubiquitin-proteasome-dependent degradation of PPAR in adipocytes The Journal of Biological Chemistry 2002 277 6 4062 4068
130. Hedvat M., Jain A., Carson D. A., Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPAR Cancer Cell 2004 5 6 565 574
131. Burgermeister E., Chuderland D., Hanoch T., Meyer M., Liscovitch M., Seger R., Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor Molecular and Cellular Biology 2007 27 3 803 817
132. Chang A. J., Song D. H., Wolfe M. M., Attenuation of peroxisome proliferator-activated receptor (PPAR ) mediates gastrin-stimulated colorectal cancer cell proliferation The Journal of Biological Chemistry 2006 281 21 14700 14710
133. Mukunyadzi P., Ai L., Portilla D., Barnes E. L., Fan C.-Y., Expression of peroxisome proliferator-activated receptor gamma in salivary duct carcinoma: immunohistochemical analysis of 15 cases Modern Pathology 2003 16 12 1218 1223
134. Papadaki I., Mylona E., Giannopoulou I., Markaki S., Keramopoulos A., Nakopoulou L., PPAR expression in breast cancer: clinical value and correlation with ER Histopathology 2005 46 1 37 42
135. Kim H. J., Hwang J. Y., Kim H. J., Expression of a peroxisome proliferator-activated receptor gamma 1 splice variant that was identified in human lung cancers suppresses cell death induced by cisplatin and oxidative stress Clinical Cancer Research 2007 13 9 2577 2583
136. Nomura S., Nakajima A., Ishimine S., Matsuhashi N., Kadowaki T., Kaminishi M., Differential expression of peroxisome proliferator-activated receptor in histologically different human gastric cancer tissues Journal of Experimental and Clinical Cancer Research 2006 25 3 443 448
137. Motomura W., Okumura T., Takahashi N., Obara T., Kohgo Y., Activation of peroxisome proliferator-activated receptor by troglitazone inhibits cell growth through the increase of p27(Kip1) in human pancreatic carcinoma cells Cancer Research 2000 60 19 5558 5564
138. Sugimura A., Kiriyama Y., Nochi H., Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor Biochemical and Biophysical Research Communications 1999 261 3 833 837
139. Lennon A. M., Ramaug M., Dessouroux A., Pierre M., MAP kinase cascades are activated in astrocytes and preadipocytes by 15-deoxy- 12-14 -prostaglandin J2 and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor gamma-independent mechanisms involving reactive oxygenated species The Journal of Biological Chemistry 2002 277 33 29681 29685
140. Patel K. M., Wright K. L., Whittaker P., Chakravarty P., Watson M. L., Ward S. G., Differential modulation of COX-2 expression in A549 airway epithelial cells by structurally distinct PPAR agonists: evidence for disparate functional effects which are independent of NF- B and PPAR Cellular Signalling 2005 17 9 1098 1110
141. Li M., Lee T. W., Mok T. S. K., Warner T. D., Yim A. P. C., Chen G. G., Activation of peroxisome proliferator-activated receptor- by troglitazone (TGZ) inhibits human lung cell growth Journal of Cellular Biochemistry 2005 96 4 760 774
142. Kim K.-H., Cho Y. S., Park J.-M., Yoon S.-O., Kim K.-W., Chung A.-S., Pro-MMP-2 activation by the PPAR agonist, ciglitazone, induces cell invasion through the generation of ROS and the activation of ERK FEBS Letters 2007 581 17 3303 3310
143. Kim E.-H., Na H.-K., Surh Y.-J., Upregulation of VEGF by 15-deoxy- 12,14 -prostaglandin J2 via heme oxygenase-1 and ERK1/2 signaling in MCF-7 cells Annals of the New York Academy of Sciences 2006 1090 375 384
144. Cao L.-Q., Chen X.-L., Wang Q., Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells Acta Pharmacologica Sinica 2007 28 6 879 887
145. Zhang W., Wu N., Li Z., Wang L., Jin J., Zha X.-L., PPAR activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404 Cancer Biology and Therapy 2006 5 8 1008 1014
146. Patel L., Pass I., Coxon P., Downes C. P., Smith S. A., Macphee C. H., Tumor suppressor and anti-inflammatory actions of PPAR agonists are mediated via upregulation of PTEN Current Biology 2001 11 10 764 768
147. Han S., Roman J., Rosiglitazone suppresses human lung carcinoma cell growth through PPAR -dependent and PPAR -independent signal pathways Molecular Cancer Therapeutics 2006 5 2 430 437
148. Lee S. Y., Hur G. Y., Jung K. H., PPAR- agonist increase gefitinibs antitumor activity through PTEN expression Lung Cancer 2006 51 3 297 301
149. Farrow B., Evers B. M., Activation of PPAR increases PTEN expression in pancreatic cancer cells Biochemical and Biophysical Research Communications 2003 301 1 50 53
150. Cho D.-H., Yoon J. C., Sangmee A. J., Troglitazone acutely inhibits protein synthesis in endothelial cells via a novel mechanism involving protein phosphatase 2A-dependent p70 S6 kinase inhibition American Journal of Physiology 2006 291 2 C317 C326
151. He G., Sung Y. M., DiGiovanni J., Fischer S. M., Thiazolidinediones inhibit insulin-like growth factor-I-induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity Cancer Research 2006 66 3 1873 1879
152. Dhillon A. S., Hagan S., Rath O., Kolch W., MAP kinase signalling pathways in cancer Oncogene 2007 26 22 3279 3290
153. Sebolt-Leopold J. S., Herrera R., Targeting the mitogen-activated protein kinase cascade to treat cancer Nature Reviews Cancer 2004 4 12 937 947
154. Wellbrock C., Karasarides M., Marais R., The RAF proteins take centre stage Nature Reviews Molecular Cell Biology 2004 5 11 875 885
155. Hoshino R., Chatani Y., Yamori T., Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors Oncogene 1999 18 3 813 822
156. Camp H. S., Tafuri S. R., Regulation of peroxisome proliferator-activated receptor activity by mitogen-activated protein kinase The Journal of Biological Chemistry 1997 272 16 10811 10816
157. Zhang B., Berger J., Zhou G., Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor The Journal of Biological Chemistry 1996 271 50 31771 31774
158. Diradourian C., Girard J., Pgorier J.-P., Phosphorylation of PPARs: from molecular characterization to physiological relevance Biochimie 2005 87 1 33 38
159. Adams M., Reginato M. J., Shao D., Lazar M. A., Chatterjee V. K., Transcriptional activation by peroxisome proliferator-activated receptor is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site The Journal of Biological Chemistry 1997 272 8 5128 5132
160. Hu E., Kim J. B., Sarraf P., Spiegelman B. M., Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPAR Science 1996 274 5295 2100 2103
161. Schoonjans K., Martin G., Staels B., Auwerx J., Peroxisome
162. Lazennec G., Canaple L., Saugy D., Wahli W., Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators Molecular Endocrinology 2000 14 12 1962 1975
163. Shao D., Rangwala S. M., Bailey S. T., Krakow S. L., Reginato M. J., Lazar M. A., Interdomain communication regulating ligand binding by PPAR- Nature 1998 396 6709 377 380
164. Hauser S., Adelmant G., Sarraf P., Wright H. M., Mueller E., Spiegelman B. M., Degradation of the peroxisome proliferator-activated receptor is linked to ligand-dependent activation The Journal of Biological Chemistry 2000 275 24 18527 18533 (Pubitemid 30414814)
165. Sung C. K., She H., Xiong S., Tsukamoto H., Tumor necrosis factor- inhibits peroxisome proliferator-activated receptor activity at a posttranslational level in hepatic stellate cells American Journal of Physiology 2004 286 5 G722 G729
166. Okura T., Nakamura M., Takata Y., Watanabe S., Kitami Y., Hiwada K., Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells European Journal of Pharmacology 2000 407 3 227 235
167. Scatena R., Bottoni P., Martorana G. E., Mitochondrial respiratory chain dysfunction, a non-receptor-mediated effect of synthetic PPAR-ligands: biochemical and pharmacological implications Biochemical and Biophysical Research Communications 2004 319 3 967 973
168. Hashimoto K., Farrow B. J., Evers B. M., Activation and role of MAP kinases in 15d-PGJ2-induced apoptosis in the human pancreatic cancer cell line MIA PaCa-2 Pancreas 2004 28 2 153 159
169. Shan Z.-Z., Masuko-Hongo K., Dai S.-M., Nakamura H., Kato T., Nishioka K., A potential role of 15-deoxy- 12,14 -prostaglandin J2 for induction of human articular chondrocyte apoptosis in arthritis The Journal of Biological Chemistry 2004 279 36 37939 37950
170. Kim J.-A., Park K.-S., Kim H.-I., Troglitazone activates p21Cip/WAF1 through the ERK pathway in HCT15 human colorectal cancer cells Cancer Letters 2002 179 2 185 195
171. Baek S. J., Wilson L. C., Hsi L. C., Eling T. E., Troglitazone, a peroxisome proliferator-activated receptor (PPAR ) ligand, selectively induces the early growth response-1 gene independently of PPAR : a novel mechanism for its anti-tumorigenic activity The Journal of Biological Chemistry 2003 278 8 5845 5853
172. Takeda K., Ichiki T., Tokunou T., Iino N., Takeshita A., 15-deoxy- 12,14 -prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells The Journal of Biological Chemistry 2001 276 52 48950 48955
173. Giulia C., Adriana L., Elisabetta P., Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling PPAR Research 2008 2008 11
174. Aldred M. A., Ginn-Pease M. E., Morrison C. D., Caveolin-1 and caveolin-2, together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis Cancer Research 2003 63 11 2864 2871
175. Vazquez F., Ramaswamy S., Nakamura N., Sellers W. R., Phosphorylation of the PTEN tail regulates protein stability and function Molecular and Cellular Biology 2000 20 14 5010 5018
176. Waite K. A., Eng C., BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels Human Molecular Genetics 2003 12 6 679 684
177. Bjornsti M.-A., Houghton P. J., The TOR pathway: a target for cancer therapy Nature Reviews Cancer 2004 4 5 335 348
178. OReilly K. E., Rojo F., She Q.-B., mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Research 2006 66 3 1500 1508
179. Luo Z., Saha A. K., Xiang X., Ruderman N. B., AMPK, the metabolic syndrome and cancer Trends in Pharmacological Sciences 2005 26 2 69 76
180. Inoki K., Zhu T., Guan K.-L., TSC2 mediates cellular energy response to control cell growth and survival Cell 2003 115 5 577 590
181. Kimura N., Tokunaga C., Dalal S., A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway Genes to Cells 2003 8 1 65 79
182. Xiang X., Saha A. K., Wen R., Ruderman N. B., Luo Z., AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms Biochemical and Biophysical Research Communications 2004 321 1 161 167 (Pubitemid 39055618)
183. Giovannucci E., Nutrition, insulin, insulin-like growth factors and cancer Hormone and Metabolic Research 2003 35 11-12 694 704
184. Pollak M., Insulin and insulin-like growth factor signalling in neoplasia Nature Reviews Cancer 2008 8 12 915 928
185. Pollak M. N., Schernhammer E. S., Hankinson S. E., Insulin-like growth factors and neoplasia Nature Reviews Cancer 2004 4 7 505 518
186. Grimberg A., Cohen P., Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis Journal of Cellular Physiology 2000 183 1 1 9
187. Lecka-Czernik B., Ackert-Bicknell C., Adamo M. L., Activation of peroxisome proliferator-activated receptor (PPAR ) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo Endocrinology 2007 148 2 903 911
188. Freudlsperger C., Moll I., Schumacher U., Thies A., Anti-proliferative effect of peroxisome proliferator-activated receptor agonists on human malignant melanoma cells in vitro Anti-Cancer Drugs 2006 17 3 325 332
189. Belli S. H., Graffigna M. N., Oneto A., Otero P., Schurman L., Levalle O. A., Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome Fertility and Sterility 2004 81 3 624 629
190. Seto-Young D., Paliou M., Schlosser J., Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production The Journal of Clinical Endocrinology Metabolism 2005 90 11 6099 6105
191. Seto-Young D., Avtanski D., Strizhevsky M., Interactions among peroxisome proliferator activated receptor-, insulin signaling pathways, and steroidogenic acute regulatory protein in human ovarian cells The Journal of Clinical Endocrinology Metabolism 2007 92 6 2232 2239
192. Hilding A., Hall K., Skogsberg J., Ehrenborg E., Lewitt M. S., Troglitazone stimulates IGF-binding protein-1 by a PPAR -independent mechanism Biochemical and Biophysical Research Communications 2003 303 2 693 699
193. Gavrilova O., Haluzik M., Matsusue K., Liver peroxisome proliferator-activated receptor contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass The Journal of Biological Chemistry 2003 278 36 34268 34276
194. He W., Barak Y., Hevener A., Adipose-specific peroxisome proliferator-activated receptor knockout causes insulin resistance in fat and liver but not in muscle Proceedings of the National Academy of Sciences of the United States of America 2003 100 26 15712 15717
195. Hevener A. L., He W., Barak Y., Muscle-specific Pparg deletion causes insulin resistance Nature Medicine 2003 9 12 1491 1497
196. Berger J. P., Role of PPAR, transcriptional cofactors, and adiponectin in the regulation of nutrient metabolism, adipogenesis and insulin action: view from the chair International Journal of Obesity 2005 29 supplement 1 S3 S4
197. Berger J. P., Akiyama T. E., Meinke P. T., PPARs: therapeutic targets for metabolic disease Trends in Pharmacological Sciences 2005 26 5 244 251
198. Okuno A., Tamemoto H., Tobe K., Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats The Journal of Clinical Investigation 1998 101 6 1354 1361
199. Quinn C. E., Hamilton P. K., Lockhart C. J., McVeigh G. E., Thiazolidinediones: effects on insulin resistance and the cardiovascular system British Journal of Pharmacology 2008 153 4 636 645
200. Berg A. H., Combs T. P., Du X., Brownlee M., Scherer P. E., The adipocyte-secreted protein Acrp30 enhances hepatic insulin action Nature Medicine 2001 7 8 947 953
201. Bruce C. R., Mertz V. A., Heigenhauser G. J. F., Dyck D. J., The stimulatory effect of globular adiponectin on insulin-stimulated glucose uptake and fatty acid oxidation is impaired in skeletal muscle from obese subjects Diabetes 2005 54 11 3154 3160
202. Kahn S. E., Haffner S. M., Heise M. A., Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy The New England Journal of Medicine 2006 355 23 2427 2443
203. Ackert-Bicknell C. L., Shockley K. R., Horton L. G., Lecka-Czernik B., Churchill G. A., Rosen C. J., Strain-specific effects of rosiglitazone on bone mass, body composition, and serum insulin-like growth factor-I Endocrinology 2009 150 3 1330 1340
204. Bruning P. F., Bonfrer J. M. G., Van Noord P. A. H., Hart A. A. M., De Jong-Bakker M., Nooijen W. J., Insulin resistance and breast-cancer risk International Journal of Cancer 1992 52 4 511 516
205. Giovannucci E., Insulin, insulin-like growth factors and colon cancer: a review of the evidence Journal of Nutrition 2001 131 11, supplement 3109S 3120S
206. Lev-Ran A., Mitogenic factors accelerate later-age diseases: insulin as a paradigm Mechanisms of Ageing and Development 1998 102 1 95 113
207. Ma J., Giovannucci E., Pollak M., A prospective study of plasma C-peptide and colorectal cancer risk in men Journal of the National Cancer Institute 2004 96 7 546 553 (Pubitemid 38559579)
208. Chen G. G., Lee J. F. Y., Wang S. H., Chan U. P. F., Ip P. C., Lau W. Y., Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and Nf- B in human colon cancer Life Sciences 2002 70 22 2631 2646
209. Copland J. A., Marlow L. A., Kurakata S., Novel high-affinity PPAR agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1 Oncogene 2006 25 16 2304 2317
210. Girnun G. D., Naseri E., Vafai S. B., Synergy between PPAR ligands and platinum-based drugs in cancer Cancer Cell 2007 11 5 395 406
211. Hafner C., Reichle A., Vogt T., New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPAR agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy Current Cancer Drug Targets 2005 5 6 393 419
212. Mustafa A., Kruger W. D., Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor agonist in an in vivo mouse model of spontaneous breast cancer Clinical Cancer Research 2008 14 15 4935 4942